93 related articles for article (PubMed ID: 16515303)
1. [Improving prognosis with docetaxel and monoclonal antibodies].
Krankenpfl J; 2005; 43(7-10):233. PubMed ID: 16515303
[No Abstract] [Full Text] [Related]
2. [Caelyx once again recommended in recurrent ovarian carcinoma].
Krankenpfl J; 2005; 43(7-10):232. PubMed ID: 16518888
[No Abstract] [Full Text] [Related]
3. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME; Curiel T; Gómez JG; Jorge M
Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
[TBL] [Abstract][Full Text] [Related]
4. [Choice of first-line chemotherapy for advanced ovarian cancer].
Tiuliandin SA
Vopr Onkol; 1999; 45(4):350-4. PubMed ID: 10532090
[No Abstract] [Full Text] [Related]
5. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
6. Second-line therapy for ovarian cancer.
Markman M
Clin Adv Hematol Oncol; 2008 Jun; 6(6):421-2. PubMed ID: 18567987
[No Abstract] [Full Text] [Related]
7. Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer.
Vergote I; Amant F
Gynecol Oncol; 2006 Sep; 102(3):415-7. PubMed ID: 16979430
[No Abstract] [Full Text] [Related]
8. Caelyx and ovarian cancer.
Eur J Cancer Care (Engl); 2001 Jun; 10(2):79. PubMed ID: 11829050
[No Abstract] [Full Text] [Related]
9. [Ovarian carcinoma. Residual therapy with pegylated liposomal doxorubicin?].
Musch A
Med Monatsschr Pharm; 2005 Dec; 28(12):453-5. PubMed ID: 16389880
[No Abstract] [Full Text] [Related]
10. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Grønlund B
Dan Med Bull; 2006 Aug; 53(3):232-57. PubMed ID: 17092448
[No Abstract] [Full Text] [Related]
11. [Therapy of advanced ovarian carcinoma].
Pfisterer J
Krankenpfl J; 2004; 42(1-2):18-9. PubMed ID: 15116769
[No Abstract] [Full Text] [Related]
12. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin.
Jones RL; Berry GJ; Rubens RD; Miles DW
Lancet Oncol; 2004 Sep; 5(9):575-7. PubMed ID: 15337488
[No Abstract] [Full Text] [Related]
13. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy of a second instance of carcinoma of the ovary].
Giaccone G; Clerico M; Donadio M; Calciati A
Minerva Ginecol; 1984 Apr; 36(4):209-12. PubMed ID: 6462524
[No Abstract] [Full Text] [Related]
15. Liposomal doxorubicin-associated acute hypersensitivity despite appropriate preventive measures.
Chan A; Shih V; Tham Chee Kian
J Oncol Pharm Pract; 2007 Jun; 13(2):105-7. PubMed ID: 17873110
[TBL] [Abstract][Full Text] [Related]
16. The ethics of early stopping rules: who is protecting whom?
Cannistra SA
J Clin Oncol; 2004 May; 22(9):1542-5. PubMed ID: 15117977
[No Abstract] [Full Text] [Related]
17. [Treatment of epithelial ovarian cancer].
Langmár Z; Csömör S
Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
[TBL] [Abstract][Full Text] [Related]
18. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
Gossner G; Coleman RL; Mutch DG; Horowitz NS; Rader JS; Gibb RK; Powell MA; Herzog TJ
Gynecol Oncol; 2006 Oct; 103(1):212-8. PubMed ID: 16677696
[TBL] [Abstract][Full Text] [Related]
19. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
20. [New 2004 guidelines of the Breast Organ Committee of AGO].
Krankenpfl J; 2004; 42(3-4):81. PubMed ID: 15311888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
